Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination

The tyrosine kinase inhibitor Gleevec may have additional uses to radiosensitize tumors that are defective in non-homologous end joining (NHEJ), with the potential to greatly expand clinical applications of this agent.